Apogee to test twice-yearly dosing of atopic dermatitis biologic
临床1期上市批准临床2期临床结果并购
Shares of Apogee Pharmaceuticals surged 42% Tuesday after the drugmaker said interim Phase I data for its IL-13 inhibitorIL-13 inhibitor suggested it could be effective at treating atopic dermatitis using a maintenance dosing schedule of every three- or six-month injections. The company plans to start a Phase II trial this half in patients with moderate to severe disease.
The candidate, APG777, is a monoclonal antibody (mAb) for inflammatory diseases designed to have a longer half-life and enable two to four yearly injections, while dosing regimens for currently approved biologics require 13 to 26 injections per year.
The Phase I trial enrolled 40 healthy adults to receive either 300mg, 600mg, or 1200mg doses of APG777. Pharmacokinetic data suggest the mAb has a half-life of about 75 days, and that a single dose can lead to a sustained inhibition of two key atopic dermatitis biomarkers – pSTAT6 and TARC – for at least three months, which is the longest follow-up data available.
The ascending doses were well-tolerated, with no severe adverse events or study discontinuations due to side effects.
Best-in-class prospects
Apogee said the data thus far suggests APG777 could be a potentially best-in-class IL-13 inhibitorIL-13 inhibitor and offer more favourable dosing than that of lebrikizumab from Eil Lilly, which already has physicians excited for its once-monthly injections and standard of care-comparable efficacy. For more, see Physician Views Results: Dermatologists see lebrikizumab's four-week dosing as an important value-add.
Lebrikizumab was approved by the European Commission in November as Ebglyss to treat patients with moderate-to-severe atopic dermatitis, but the FDA issued a complete response letter in October, citing issues at a third-party contract manufacturing organisation.
Almirall has rights to the IL-13-targeting mAb in Europe after licensing them from Eli Lilly, which itself gained the drug through its $1.1-billion takeover of Dermira in 2020.
In Apogee’s head-to-head preclinical studies, APG777 demonstrated equivalent or better inhibition of IL-13 signalling compared with lebrikizumab.
For the randomised, placebo-controlled Phase II study, Apogee expects to administer six injections of APG777 during the 16-week induction period, whereas lebrikizumab requires 11 over the same period. The company will then test a maintenance dosing schedule of every three- or six-month injections.
Topline data for the trial are expected in the second half of 2025.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。